CB4211 MOTS-c Analog in NAFLD - AASLD 2021

AASLD Conference

CohBar Inc.

Summary

THE ONLY HUMAN TRIAL of any MOTS-c-related compound

Study Details

Study Design

Phase 1a/1b RCT (double-blind, placebo-controlled)

Indication

NAFLD/NASH, obesity

Intervention

25 mg once daily subcutaneous

Species

Human

Sample Size

20 subjects

Risk of Bias Assessment

Sponsor-conducted trial